ArticleEClinicalMedicine2026
Use of procalcitonin point-of-care testing to guide de-escalation of antibiotic therapy in adults with suspected bacterial sepsis in a tertiary hospital in Bangladesh: a randomised controlled open-label trial.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05955612 (Use of Procalcitonin Point-of-care Test to Guide De-escalation of Empiric Antibiotic Therapy in Adult Patients With Sepsis in a Tertiary Hospital in Bangladesh), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Procalcitonin Point-of-care Test to Guide De-escalation of Empiric Antibiotic Therapy in Adult Patients With Sepsis in a Tertiary Hospital in Bangladesh (PROCALBAN): a Phase 3 Randomised, Controlled, Open-label Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
Background: Important drivers of antibiotic resistance in low- and middle-income countries (LMICs) include antibiotic overuse and scarcity of microbiological diagnostics. Procalcitonin point-of-care testing is a potential tool to guide antibiotic de-escalation in patients admitted with suspected bacterial sepsis. Methods: In an open-label randomised controlled clinical trial in Chittagong Medical College Hospital in Bangladesh, adult patients with suspected bacterial sepsis were randomised to procalcitonin (PCT)-guided de-escalation of antibiotic therapy or standard-of-care. In the intervention group, serum procalcitonin was assessed daily and clinicians received a non-binding advice to stop antibiotics after 72 h if procalcitonin dropped below pre-defined threshold concentrations (0.5 ng/mL or 80% from the peak value if baseline value > 2 ng/mL). The primary endpoint was length of antibiotic therapy analysed by intention-to-treat. The study is registered with ClinicalTrials.gov (NCT05955612) and was completed in July 2024. Findings: Between 26 July 2023 and 20 June 2024, 532 of the 1002 patients screened for eligibility were randomly assigned to procalcitonin-guided antibiotic therapy (n = 266) or standard-of-care (n = 266). Follow-up was completed on 30 July 2024. Median (interquartile range [IQR]) length of antibiotic therapy was 4.7 (2.8-8.0) days with procalcitonin-guided therapy compared to 9.0 (5.8-12.0) days in the control arm (p < 0.0001). Mortality was similar between the two groups. In the procalcitonin-guided arm, 23 of 265 participants died (8.7%; 95% confidence interval [CI], 5.6%-12.7%), compared with 21 of 265 participants (7.9%; 95% CI, 5.0%-11.9%) in the control arm. The absolute risk difference was 0.8 percentage points (95% CI, -3.9 to 5.5 percentage points) (p = 0.875). Following review, the Data Safety Monitoring Board did not identify any deaths as attributable to antibiotic discontinuation. The incidence of recurrent infections was 8/265 (3.0%) in procalcitonin-guided antibiotic therapy and 10/265 (3.8%) in the control arm (p = 0.811). Interpretation: In this single-centre trial in Bangladesh, procalcitonin-guided de-escalation reduced the duration of antibiotic therapy in adults with suspected bacterial sepsis. Mortality and recurrent infection were similar between the groups, although the trial was not powered to assess these outcomes formally. This promising approach of point-of-care procalcitonin-guided antibiotic discontinuation should be evaluated further in comparable resource-limited settings. Funding: Wellcome Trust of Great Britain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.